SWOG clinical trial number
S9703
Phase II Trial of Antibiotic Eradication of Helicobacter Pylori and, Failing That, Systemic Chemotherapy with CHOP and Local Therapy with Involved Field Radiation in Patients with Malt Lymphomas
Closed
Phase
Accrual
0%
Research committees
Lymphoma
Treatment
Radiation Therapy
clarithromycin
metronidazole
omeprazole
tetracycline
CHOP
RT
Eligibility Criteria Expand/Collapse
Biopsy proven gastric or duodenal mucosa-associated lymphoma tissue (MALT) non-Hodgkin's lymphoma; Stage IE or IIE1; neg. BM biopsy; neg. chest x-ray or scan; positive for H. pylori; no prior chemo or RT for lymphoma; no AIDS or HIV.
Other Clinical Trials
SWOG Clinical Trial Number
S2506
MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
69%
Open
Phase